Jonathan Young is Executive Vice President and COO of Akero Therapeutics, a company he co-founded to advance promising new therapeutics to treat metabolic disease. Jonathan joined Apple Tree Partners as a Venture Partner in 2016 and has more than 15 years of experience in drug development, biotech law, and public policy.
Prior to joining ATP, Jonathan served as General Counsel and Vice President of Policy/Advocacy at Braeburn Pharmaceuticals, Inc., an ATP portfolio company. Jonathan held multiple cross-functional leadership roles at Braeburn, including efforts related to US marketing approval for Probuphine (buprenorphine) subdermal implant; licensing and development of the CAM-2038 buprenorphine injection depot product candidates; acquisition and development of the BB-0817 risperidone implant product candidate and the MedLaunch implant platform; and work to increase federal limits on buprenorphine prescribing for the treatment of opioid addiction.
Prior to joining Braeburn, Jonathan was Partner and General Counsel of FoxKiser, a Washington, D.C. law firm specializing in regulatory approval and life cycle management for pharmaceutical and biotechnology companies. Jonathan was appointed by President Barack Obama and confirmed by the US Senate to serve as Chairman of the National Council on Disability, an independent federal agency advising the President and Congress on disability policy, and previously coordinated White House disability policy for President Bill Clinton.
Jonathan earned a Ph.D. in American history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School.